Daraxonrasib for Pancreatic Cancer: What Patients Should Know
Posted in
Pancreatic cancer is one of the most difficult cancers to treat, in part because it is often diagnosed after it has spread. A newly FDA-approved targeted therapy called daraxonrasib, sold under the brand name Rasonque, now offers another treatment option for certain adults with metastatic pancreatic adenocarcinoma.
Daraxonrasib is a once-daily pill that targets RAS proteins, which can drive the growth of pancreatic cancer. In the phase 3 RASolute 302 trial, patients who received daraxonrasib had a median overall survival of 13.2 months, compared with 6.7 months for patients who received standard chemotherapy. Individual outcomes can vary, and the treatment also carries potential risks and side effects.
Agnel Raparthi, M.D., a board-certified hematologist and oncologist at the INTEGRIS Health Cancer Institute, explains how daraxonrasib works, who may be eligible and what patients should discuss with their cancer care team.
“Daraxonrasib represents a very important milestone in pancreatic cancer treatment, as for decades, pancreatic cancer has been one of the most difficult cancers to treat,” Raparthi says. “For many patients, especially those whose cancer has progressed after chemotherapy, the possibility of targeting a key cancer-driving pathway offers a level of hope we have rarely been able to provide in this disease. The work ahead is to understand who benefits most, how to manage side effects and how to build on this progress.”
What is daraxonrasib and how does it work?
What to know: Daraxonrasib is an oral, once-daily targeted therapy developed for RAS-mutated cancers, with a particular focus on metastatic pancreatic ductal adenocarcinoma (PDAC). Unlike traditional chemotherapy, it works by interfering with the specific molecular signals that drive tumor growth in patients with RAS mutations. These distinctions make it a meaningful departure from standard treatment approaches.
- Daraxonrasib is taken as a pill once daily, rather than delivered through an IV infusion.
- The drug targets RAS signaling pathways, which are molecular "switches" that, when stuck in the "on" position, tell cancer cells to keep multiplying.
- RAS mutations are present in roughly 90% of pancreatic ductal adenocarcinoma cases, making this a large potential patient population.
- Because daraxonrasib acts on a specific genetic driver of tumor growth, it belongs to the category of "targeted therapy" rather than broad-spectrum chemotherapy.
- This targeted approach aims to disrupt cancer cell growth while sparing more healthy tissue than conventional chemo typically does.
The impressive survival rates in the latest trials
What to know: The phase 3 RASolute 302 trial produced results that oncologists are describing as record-breaking for this disease. The data showed that daraxonrasib nearly doubled median overall survival compared with standard chemotherapy in patients with previously treated metastatic PDAC. Progression-free survival and tumor response rates also showed meaningful improvement.
- Patients treated with daraxonrasib in the trial showed nearly double the median overall survival compared to those receiving chemotherapy.
- The trial focused on patients with RAS-mutated metastatic pancreatic ductal adenocarcinoma who had received prior treatment.
Median overall survival
This is the metric researchers use to describe how long patients live, on average, after starting treatment. When a drug nearly doubles that number, it's significant. Still, it's worth understanding what that means in practical terms.
- "Median" survival means half of the patients lived longer than this figure, and half did not.
- Nearly doubling median survival in a cancer as aggressive as metastatic PDAC is considered a major clinical milestone.
- In the trial population, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy.
- Daraxonrasib was shown to reduce the risk of death by 60% for clinical trial participants compared to chemotherapy.
- These are trial results from a specific patient population, and outcomes for any individual patient may differ.
Progression-free survival and tumor response
- Progression-free survival, the length of time patients lived without their cancer growing, improved in the daraxonrasib group at 7.2 months versus 3.6 months compared to chemotherapy.
- Measurable tumor shrinkage was higher in the daraxonrasib group.
- A higher proportion of patients achieved disease control, meaning their cancer stabilized or shrank rather than progressing.
Quality of life and side effects
- Patients in the daraxonrasib group reported better quality-of-life scores compared to those receiving chemotherapy.
- The side-effect profile of daraxonrasib appeared more favorable than that of chemotherapy in the trial.
- That said, all medications carry risks, and patients should discuss potential side effects with their oncologist before making any decisions.
What are the potential side effects?
Like all cancer treatments, daraxonrasib can cause side effects.
- FDA warnings and precautions include skin and soft-tissue reactions, mouth inflammation and other oral disorders, diarrhea, gastrointestinal perforation, interstitial lung disease or pneumonitis, and harm to an unborn baby.
- Patients should review the full risks, symptoms to watch for and possible drug interactions with their oncology team.
- Patients should contact their care team about new or worsening symptoms. Treatment decisions should be based on an individualized discussion of potential benefits and risks.
Who might benefit from daraxonrasib today?
What to know: Daraxonrasib received full FDA approval on Aug. 26, 2026, opening several pathways for patients who may be eligible. The prior trial population consisted of patients with RAS-mutated metastatic pancreatic ductal adenocarcinoma who had already received treatment. Patients interested in accessing this therapy should speak with their oncologist.
- Daraxonrasib was studied in patients with metastatic PDAC who had already received at least one prior line of treatment.
- Previously, before FDA approval, patients must have had RAS-mutated tumors to be candidates, and genetic testing was required to confirm this.
- Now that full FDA approval has been granted, access to treatment has expanded and is no longer limited to certain access programs or clinical trial enrollment.
- The FDA approval applies to eligible patients with or without an identified RAS tumor mutation. Genetic or molecular testing may still help inform an individual patient's overall treatment plan, but is not a universal requirement for receiving daraxonrasib for eligible patients.
- Because eligibility is specific, a conversation with an oncologist familiar with this medication is an important first step.
Who may be eligible for daraxonrasib?
Daraxonrasib is approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
- A patient’s oncologist will consider the cancer diagnosis, previous treatments, overall health, other medical conditions and the drug’s potential risks before recommending treatment.
- The FDA-approved indication does not require patients to have a confirmed RAS mutation or complete a companion diagnostic test. However, molecular testing may still provide useful information about a patient’s cancer and other possible treatment options.
What this means for the future of pancreatic cancer treatment
What to know: Researchers and oncologists are calling the RASolute 302 results a potential inflection point in how metastatic pancreatic cancer is treated. These findings could reshape expectations around pancreatic cancer survival rates, especially now that daraxonrasib received FDA approval and becomes part of standard care. Research is already expanding to explore daraxonrasib in earlier-stage disease and in combination with other therapies.
- Some oncologists have described daraxonrasib as a potential new standard of care in previously treated metastatic PDAC, with FDA approval now paving the way forward.
- The trial results prompted a broader reassessment of what's achievable in pancreatic cancer treatment.
- Earlier-stage studies and combination regimens are already being explored to determine whether these benefits can extend further.
- The development of daraxonrasib reflects broader progress in targeting RAS mutations, a challenge scientists have worked on for decades.
Talk with an INTEGRIS Health cancer specialist
Next steps: Treatment options for metastatic pancreatic cancer are changing quickly. An INTEGRIS Health oncologist can review your diagnosis, previous treatments, overall health and personal goals to help determine whether daraxonrasib or another treatment may be appropriate. Find an INTEGRIS Health cancer specialist to discuss your treatment options.
This article was medically reviewed by Agnel Raparthi, M.D., a board-certified hematologist and oncologist in Oklahoma City.
